Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | President brtxDISC Division | July 12, 2017 | July 14, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date July 12, 2017 · Filed July 14, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.80 · Expires 2027-07-12 | Direct | 110,000 |
Reported balance
After 2017-07-12 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2017-07-12 · Grant · Acquired 110,000 · Balance 110,000 F4: The option is exercisable to the extent of 36,667 shares on each of July 12, 2018 and July 12, 2019, and 36,666 shares on July 12, 2020. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2025-02-09 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2017-07-12 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 25,000 F1: The option vests to the extent of 8,334 shares on February 9, 2016 and 8,333 shares on each of February 9, 2017 and February 9, 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $4.70 · Expires 2025-09-04 | Direct | 25,000 |
Reported balance
Holding disclosure · report date 2017-07-12 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 25,000 F2: The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018. |
| OptionSEC Table II · derivative / convertible security · Conversion / exercise price $3.73 · Expires 2026-06-10 | Direct | 80,000 |
Reported balance
Holding disclosure · report date 2017-07-12 · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · Balance 80,000 F3: The option is exercisable to the extent of 26,667 shares on each of June 10, 2017 and June 10, 2018, and 26,666 shares on June 10, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests to the extent of 8,334 shares on February 9, 2016 and 8,333 shares on each of February 9, 2017 and February 9, 2018.
F2: The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018.
F3: The option is exercisable to the extent of 26,667 shares on each of June 10, 2017 and June 10, 2018, and 26,666 shares on June 10, 2019.
F4: The option is exercisable to the extent of 36,667 shares on each of July 12, 2018 and July 12, 2019, and 36,666 shares on July 12, 2020.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 12, 2017 Filed Jul 14, 2017 11:17 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 110,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001140361-17-027860 · doc1.xml · derivative · entry 4 Field Edward L. · CIK 0001435185 · President brtxDISC Division 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2027-07-12 F4 · derivative.exercise_date: The option is exercisable to the extent of 36,667 shares on each of July 12, 2018 and July 12, 2019, and 36,666 shares on July 12, 2020. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 16:41 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 25,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007725 · doc1.xml · derivative · entry 4 Field Edward L. · CIK 0001435185 · President brtxDISC Division 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2025-09-04 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 16:41 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 25,000 | Not disclosed Strike: $7.00 | Not disclosed |
DisclosureSEC source: 0001140361-17-007725 · doc1.xml · derivative · entry 3 Field Edward L. · CIK 0001435185 · President brtxDISC Division 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-09-04 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 8,334 shares on September 4, 2016 and 8,333 shares on each of September 4, 2017 and September 4, 2018. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 16:41 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantOption · Derivative | 25,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001140361-17-007725 · doc1.xml · derivative · entry 2 Field Edward L. · CIK 0001435185 · President brtxDISC Division 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2025-02-09 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 8,334 shares on February 9, 2016 and 8,333 shares on each of February 9, 2017 and February 9, 2018. Read SEC document |
| February 14, 2017 Filed Feb 15, 2017 16:41 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerOption · Derivative | 25,000 | Not disclosed Strike: $9.20 | Not disclosed |
DisclosureSEC source: 0001140361-17-007725 · doc1.xml · derivative · entry 1 Field Edward L. · CIK 0001435185 · President brtxDISC Division 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2025-02-09 F4 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option vests to the extent of 8,334 shares on February 9, 2016 and 8,333 shares on each of February 9, 2017 and February 9, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.